Application of glabridin liposomes in the preparation of drugs for the treatment of acute (chronic) cardiotoxicity induced by doxorubicin

Abstract

The invention discloses an application of glabridin lipidosome in preparing a drug for treating acute (chronic) cardiotoxicity induced by adriamycin. An appropriate amount of cholesterol, lecithin andglabridin are mixed, a chloroform-methanol mixed solution is added, a uniform lipid dry membrane is prepared by adopting a rotary film evaporation method, then a phosphoric acid buffer salt solutionwith a PH of 7 is added, the lipid membrane is sufficiently swelled and hydrated and is ultrasonically dispersed for 5 min under ultrasonic power of 400 W, and the glabridin lipdosome is obtained. Byvirtue of pretreatment of glabridin lipidosome for C57BL / 6 mice, then the mice are injected with adriamycin, and a myocardial enzyme level is reduced; and the weight loss of the mice is gradually reduced, which proves that the glabricin can alleviate the cardiotoxicity induced by the adriamycin and is safe and low in toxicity to normal cells of the human body.

Description

technical field

[0001] The invention belongs to the field of Chinese herbal medicines, and in particular relates to a new application of glabridin liposome in reducing myocardial toxicity caused by doxorubicin. Background technique

[0002] Heart failure is a complex clinical symptom group, which is a severe stage of various heart diseases. Its incidence rate is high, and its five-year survival rate is similar to that of malignant tumors. Half of the patients diagnosed with heart failure will die within 4 years, and the 1-year mortality rate of patients with severe heart failure is as high as 50%. Unlike other cardiovascular diseases, age-adjusted mortality from heart failure is still on the rise. Heart failure has increasingly become the most common and most harmful disease among cardiovascular diseases, and the causes of heart failure are very complex and diverse. Therefore, heart failure has become the focus and difficulty in the field of cardiovascular disease research....

Examples

Embodiment 1

[0024] [Example 1] Glabridin liposome preparation and characterization detection

[0025] (1) Glabridin liposome preparation

[0026] 1. Preparation method:

[0027] Weigh cholesterol, lecithin and glabridin and put them in a container, add chloroform-methanol mixed solution, the volume ratio of chloroform to methanol in the chloroform-methanol mixed solution=2:1, rotate at 50-60°C by rotary thin film evaporation method Make a film for 20-50min to make a uniform lipid dry film; the thickness of the lipid dry film is 0.1-0.2mm; dry the residual solvent with nitrogen, then add phosphate buffered saline solution with pH=7 to make the lipid film Fully swollen and hydrated, ultrasonicated for 5 minutes under the condition of ultrasonic power 400W, to obtain final product; in the ultrasonic, the frequency of ultrasonic for 5 seconds and stop for 5 seconds is carried out; the mass ratio of cholesterol to lecithin is cholesterol:lecithin=1: 5. The molar ratio of glabridin to lecithi...

Embodiment 2

[0071] [Example 2] Research on the effect of glabridin liposome on reducing the acute myocardial toxicity caused by doxorubicin

[0072] (1) Grouping and handling of animals

[0073] 6-8 weeks old C57BL / 6 male mice, 10 in each group, were divided into normal control group, model control group and glabridin liposome treatment group. (1) The normal control group was injected intraperitoneally with the same amount of normal saline every day for 7 consecutive days; (2) The model control group was injected with the same amount of normal saline intraperitoneally every day for 6 consecutive days, and DOX (doxorubicin) 20 mg / kg was injected intraperitoneally on the 7th day; ( 3) The glabridin liposome low-dose experimental group was injected intraperitoneally with 15 mg / kg glabridin liposome every day for 6 consecutive days, and on the seventh day, intraperitoneally injected DOX (doxorubicin) 20 mg / kg; (4) glabridin The liposome high-dose experimental group was injected intraperitone...

technical field

[0001] The invention belongs to the field of Chinese herbal medicines, and in particular relates to a new application of glabridin liposome in reducing myocardial toxicity caused by doxorubicin. Background technique

[0002] Heart failure is a complex clinical symptom group, which is a severe stage of various heart diseases. Its incidence rate is high, and its five-year survival rate is similar to that of malignant tumors. Half of the patients diagnosed with heart failure will die within 4 years, and the 1-year mortality rate of patients with severe heart failure is as high as 50%. Unlike other cardiovascular diseases, age-adjusted mortality from heart failure is still on the rise. Heart failure has increasingly become the most common and most harmful disease among cardiovascular diseases, and the causes of heart failure are very complex and diverse. Therefore, heart failure has become the focus and difficulty in the field of cardiovascular disease research....

Examples

Embodiment 1

[0024] [Example 1] Glabridin liposome preparation and characterization detection

[0025] (1) Glabridin liposome preparation

[0026] 1. Preparation method:

[0027] Weigh cholesterol, lecithin and glabridin and put them in a container, add chloroform-methanol mixed solution, the volume ratio of chloroform to methanol in the chloroform-methanol mixed solution=2:1, rotate at 50-60°C by rotary thin film evaporation method Make a film for 20-50min to make a uniform lipid dry film; the thickness of the lipid dry film is 0.1-0.2mm; dry the residual solvent with nitrogen, then add phosphate buffered saline solution with pH=7 to make the lipid film Fully swollen and hydrated, ultrasonicated for 5 minutes under the condition of ultrasonic power 400W, to obtain final product; in the ultrasonic, the frequency of ultrasonic for 5 seconds and stop for 5 seconds is carried out; the mass ratio of cholesterol to lecithin is cholesterol:lecithin=1: 5. The molar ratio of glabridin to lecithi...

Embodiment 2

[0071] [Example 2] Research on the effect of glabridin liposome on reducing the acute myocardial toxicity caused by doxorubicin

[0072] (1) Grouping and handling of animals

[0073] 6-8 weeks old C57BL / 6 male mice, 10 in each group, were divided into normal control group, model control group and glabridin liposome treatment group. (1) The normal control group was injected intraperitoneally with the same amount of normal saline every day for 7 consecutive days; (2) The model control group was injected with the same amount of normal saline intraperitoneally every day for 6 consecutive days, and DOX (doxorubicin) 20 mg / kg was injected intraperitoneally on the 7th day; ( 3) The glabridin liposome low-dose experimental group was injected intraperitoneally with 15 mg / kg glabridin liposome every day for 6 consecutive days, and on the seventh day, intraperitoneally injected DOX (doxorubicin) 20 mg / kg; (4) glabridin The liposome high-dose experimental group was injected intraperitone...

Images